免疫检查点抑制剂在120例黑色素瘤患者中引起的皮肤表现——欧洲MelSkinTox研究
该研究为欧洲多中心IV期上市后研究,纳入120例接受免疫检查点抑制剂治疗的黑色素瘤患者,通过随访问卷收集2016年11月至2021年3月数据。结果显示炎性良性皮肤病最常见(52.5%),多数皮肤irAE导致免疫治疗继续(88.0%),完全缓解与更严重的皮肤irAE相关,平均起病时间为208天。
要点
- 炎性良性皮肤病最常见(n=63,52.5%),其次为药物相关皮疹(n=24,20%)、色素性疾病(n=23,19.2%)和大疱性疾病(n=10,8.3%)。
- II级皮肤irAE(n=41,34.2%)包括大疱性类天疱疮、湿疹、脂膜炎、苔藓样疹、斑丘疹、瘙痒、银屑病样皮疹、荨麻疹样皮疹和白癜风。
- 大多数皮肤irAE导致免疫治疗继续(n=95,88.0%),完全缓解与更严重的皮肤irAE相关,平均起病时间为208天,部分为迟发型。
核心结论
- 本研究描述了皮肤irAE的临床谱、发生时间和严重程度及其与肿瘤反应的关系。
- I-II级皮肤irAE易于管理,允许继续抗癌治疗。
- 严重的迟发型皮肤irAE并不少见,皮肤科随访有助于减轻危及生命不良事件的风险。
- 这些发现强调肿瘤皮肤科参与接受免疫治疗的黑色素瘤患者管理的重要性。
研究设计与样本
- 欧洲多中心IV期上市后研究,使用随访问卷,数据来自MelSkinTox数据库(欧洲多中心生物样本库,专注于黑色素瘤和皮肤不良事件随访,由EADO支持)。
- 数据收集时间从2016年11月至2021年3月,纳入接受ICI治疗的黑色素瘤患者。
- 报告的皮肤病分为四类:炎性皮肤病、大疱性疾病、药物相关皮疹和色素性疾病。
主要发现
- 炎性良性皮肤病(n=63)占最常见反应组(52.5%)。
- 药物相关皮疹(n=24,20%)、色素性疾病(n=23,19.2%)和大疱性疾病(n=10,8.3%)依次排列。
- II级(n=41,34.2%)包括大疱性类天疱疮、湿疹、脂膜炎、苔藓样疹、斑丘疹、瘙痒、银屑病样皮疹、荨麻疹样皮疹和白癜风。
- III级(n=18,15.0%)包括大疱性类天疱疮、苔藓样疹和皮疹;IV级(n=2,1.7%)仅包括大疱性疾病。
- 大多数皮肤irAE导致免疫治疗继续(n=95,88.0%),完全缓解与更严重的皮肤irAE相关,平均起病时间为208天,部分为迟发型事件。
关键数值与推荐
- 皮肤irAE影响近40%的PD-1i治疗患者和50%的CTLA4i治疗患者(原文背景)。
- 炎性良性皮肤病n=63(52.5%)、药物相关皮疹n=24(20%)、色素性疾病n=23(19.2%)、大疱性疾病n=10(8.3%)。
- II级n=41(34.2%)、III级n=18(15.0%)、IV级n=2(1.7%)。
- 免疫治疗继续n=95(88.0%),平均起病时间208天。
临床怎么用
- I-II级皮肤irAE易于管理,允许继续抗癌治疗(原文结论)。
- 严重的迟发型皮肤irAE并不少见(原文结论)。
- 皮肤科随访有助于减轻危及生命不良事件的风险(原文结论)。
- 这些发现强调肿瘤皮肤科参与接受免疫治疗的黑色素瘤患者管理的重要性(原文结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune-related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD-1i and 50% of CTLA4i-treated patients. Severe cutaneous irAE do not often occur but could be life-threatening and may persist despite treatment discontinuation. METHODS: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real-world, phase IV, post-marketing study using a follow-up questionnaire. Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow-up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug-related eruptions and pigmentary diseases. RESULTS: Inflammatory benign dermatoses (n = 63) represented the most common group of reactions (52.5%), followed by drug-related eruptions (n = 24, 20%), pigmentary diseases (n = 23, 19.2%) and bullous diseases (n = 10, 8.3%). Grade II (n = 41, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis-like rash, urticarial eruption and vitiligo. Grade III (n = 18, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (n = 2, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (n = 95, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time-to-onset of 208 days and some late-onset events. CONCLUSION: Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I-II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late-onset cutaneous irAE are not uncommon. A dermatological follow-up helps mitigate the risk of life-threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.
引用
- L'Orphelin JM, Cassecuel J, Kandolf L, et al. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study. J Eur Acad Dermatol Venereol. 2023. PMID: 37042810. doi:10.1111/jdv.19112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。